Cel Sci (CVM) Interest Expenses (2010 - 2026)
Cel Sci (CVM) posted Interest Expenses of $7.6 million for Q1 2026, up 4535.59% sequentially from $164553.0 in Q4 2025, and up 4185.39% YoY from $178000.0 in Q1 2025.
Cel Sci (CVM) Interest Expenses (2010 - 2026) Analysis & Trends
Cel Sci has reported Interest Expenses for 17 years, with the latest figure at $7.6 million in Q1 2026.
- Quarterly Interest Expenses rose 4185.39% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (up 634.09% YoY) and the FY2025 annual result came in at $65.9 million, up 5.45% from the prior year.
- Interest Expenses improved to $7.6 million in Q1 2026 per CVM's latest filing, from $164553.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $18.2 million in Q1 2022 and troughed at $39483.0 in Q3 2024.
- A 5-year average of $7.5 million and a median of $7.6 million in 2026 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2025: Interest Expenses soared 62825.0% in 2022, then slumped 98.64% in 2025.
- Over 5 years, Interest Expenses stood at $300000.0 in 2022, then soared by 4486.0% to $13.8 million in 2023, then sank by 98.49% to $207735.0 in 2024, then retreated by 20.79% to $164553.0 in 2025, then soared by 4535.59% to $7.6 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $7.6 million, $164553.0, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Cel Sci | 2.16 Mn | -4.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.63 Mn |
| Mar 31, 2026 | 7.63 Mn |
| Dec 31, 2025 | 164,553.00 |
| Dec 31, 2025 | 164,553.00 |
| Sep 30, 2025 | 1.89 Mn |
| Sep 30, 2025 | 1.89 Mn |
| Jun 30, 2025 | 9.73 Mn |
| Jun 30, 2025 | 9.73 Mn |
| Mar 31, 2025 | 178,000.00 |
| Mar 31, 2025 | 178,000.00 |
| Dec 31, 2024 | 207,735.00 |
| Dec 31, 2024 | 207,735.00 |
| Sep 30, 2024 | 39,483.00 |
| Sep 30, 2024 | 39,483.00 |
| Jun 30, 2024 | 12.46 Mn |
| Jun 30, 2024 | 12.46 Mn |
| Mar 31, 2024 | 13.12 Mn |
| Mar 31, 2024 | 13.12 Mn |
| Dec 31, 2023 | 13.76 Mn |
| Dec 31, 2023 | 13.76 Mn |